May 30, 2014 8:05 am EDT Heat Biologics Receives Green Light to Expand Enrollment of Its Phase 1/2 Study of HS-410 in Bladder Cancer Based on Encouraging Preliminary Safety Results
Apr 09, 2014 12:00 pm EDT Heat Biologics, Inc. Presents Proprietary Allogeneic Cell Line Antigen Screening Algorithm and Systematic Analysis of Combination Tumor Immunotherapy Preclinical Data at the 105th Annual Meeting of the American Association for Cancer Research
Apr 01, 2014 7:35 am EDT Heat Biologics, Inc. Reports 2013 Fourth Quarter and Full Year Financial Results
Mar 26, 2014 4:15 pm EDT Heat Biologics, Inc. to Present at the MaidStone Life Sciences Fourth Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference on Thursday, March 27, 2014
Mar 19, 2014 8:00 am EDT Heat Biologics, Inc. Submits Revised Protocol to FDA for Phase 2 Clinical Study of HS-110 for the Treatment of Non-Small Cell Lung Cancer
Mar 10, 2014 8:05 am EDT Heat Biologics, Inc. Presents Preclinical Data From Comparative Combination Cancer Immunotherapy Research Study at Keystone Symposia on Immune Evolution in Cancer
Mar 05, 2014 8:05 am EST Heat Biologics, Inc. Appoints Taylor H. Schreiber, M.D., PH.D. as Vice President of Research and Development
Mar 03, 2014 8:05 am EST Heat Biologics Commences Dosing of First Patient in Phase 1/2 Study of Novel Cancer Immunotherapy Product Candidate HS-410 for the Treatment of Bladder Cancer
Feb 04, 2014 8:05 am EST Heat Biologics, Inc. to Present at 16th Annual BIO CEO & Investor Conference on Tuesday, February 11, 2014